Heart Failure Reviews

, Volume 17, Issue 4, pp 597–613

Atrial fibrillation and heart failure in the elderly


DOI: 10.1007/s10741-011-9290-y

Cite this article as:
Kazemian, P., Oudit, G. & Jugdutt, B.I. Heart Fail Rev (2012) 17: 597. doi:10.1007/s10741-011-9290-y


Atrial fibrillation (AF) is a common clinical problem in elderly patients and especially in those with heart failure (HF). It is a major risk factor for serious cardiovascular events, such as stroke, HF and premature death. Both the prevalence and incidence of AF increase with age and its prevalence in the United States are estimated at more than 2.2 million, with nearly 75% of patients aged >65 years. Aging-related atrial remodeling with fibrosis, dilation and mitochondrial DNA mutations predispose elderly patients to AF. Current management options for AF, including rate control and anticoagulation therapy, can be successfully applied to the elderly population. New antiarrhythmic and anticoagulation medications such as dronedarone and dabigatran, respectively, can impact the approach to therapy in the elderly. Non-pharmacological options such as catheter-based ablation have also gained prominence and have been incorporated into the guidelines for management of AF. However, more trials in the elderly and very elderly segments are needed to clarify the safety and long-term efficacy of the new treatment options.


Atrial fibrillation Heart failure Aging Antiarrhythmics Anticoagulation Catheter ablation 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Pedram Kazemian
    • 1
  • Gavin Oudit
    • 1
  • Bodh I. Jugdutt
    • 1
  1. 1.Department of Medicine, 2C2 Walter MacKenzie Health Sciences Centre, Division of CardiologyUniversity of Alberta and HospitalEdmontonCanada

Personalised recommendations